Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients
Clinical trial NCT01284569 · COMPLETED
Trial details
- NCT number
- NCT01284569
- Sponsor
- Ablynx, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-01
- Primary completion
- 2012-09-01
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.